CL2017001661A1 - Compuestos biciclicos fusionados para el tratamiento de una enfermedad. - Google Patents

Compuestos biciclicos fusionados para el tratamiento de una enfermedad.

Info

Publication number
CL2017001661A1
CL2017001661A1 CL2017001661A CL2017001661A CL2017001661A1 CL 2017001661 A1 CL2017001661 A1 CL 2017001661A1 CL 2017001661 A CL2017001661 A CL 2017001661A CL 2017001661 A CL2017001661 A CL 2017001661A CL 2017001661 A1 CL2017001661 A1 CL 2017001661A1
Authority
CL
Chile
Prior art keywords
treatment
disease
bicyclic compounds
fused bicyclic
compounds
Prior art date
Application number
CL2017001661A
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Anthony Pratt
Raju Mohan
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55300724&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001661(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of CL2017001661A1 publication Critical patent/CL2017001661A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2017001661A 2014-12-22 2017-06-22 Compuestos biciclicos fusionados para el tratamiento de una enfermedad. CL2017001661A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462095646P 2014-12-22 2014-12-22

Publications (1)

Publication Number Publication Date
CL2017001661A1 true CL2017001661A1 (es) 2018-03-23

Family

ID=55300724

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001661A CL2017001661A1 (es) 2014-12-22 2017-06-22 Compuestos biciclicos fusionados para el tratamiento de una enfermedad.

Country Status (15)

Country Link
US (5) US10167294B2 (enExample)
EP (1) EP3237419B1 (enExample)
JP (2) JP2017538773A (enExample)
KR (1) KR20170117030A (enExample)
CN (1) CN107438612A (enExample)
AU (2) AU2015370588B2 (enExample)
BR (1) BR112017013568A2 (enExample)
CA (1) CA2971755A1 (enExample)
CL (1) CL2017001661A1 (enExample)
CO (1) CO2017007121A2 (enExample)
IL (1) IL252849B (enExample)
MX (1) MX369623B (enExample)
RU (2) RU2741387C2 (enExample)
SG (1) SG11201704770YA (enExample)
WO (1) WO2016103037A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2741387C2 (ru) * 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
TW201808283A (zh) * 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2021014349A1 (en) 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
TW202114672A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 使用fxr促效劑的肝臟疾病之組合治療
KR20220054608A (ko) 2019-09-03 2022-05-03 노파르티스 아게 ActRII 수용체 길항제를 포함하는 간 질환 또는 장애 치료제
JP2022548617A (ja) 2019-09-19 2022-11-21 ノバルティス アーゲー Fxrアゴニストを含む処置
CN114502198A (zh) 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗
EP4076454A1 (en) 2019-12-20 2022-10-26 Novartis AG Combination treatment of liver diseases using integrin inhibitors
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
WO2022137082A1 (en) 2020-12-22 2022-06-30 Novartis Ag Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
KR20230124665A (ko) 2020-12-22 2023-08-25 노파르티스 아게 Cgas 관련 병태의 치료에 유용한 인돌 유도체
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
WO2007070796A1 (en) * 2005-12-15 2007-06-21 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
RU2741387C2 (ru) * 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Also Published As

Publication number Publication date
CO2017007121A2 (es) 2017-10-31
EP3237419B1 (en) 2021-02-17
RU2017126128A (ru) 2019-01-29
SG11201704770YA (en) 2017-07-28
WO2016103037A1 (en) 2016-06-30
US20240025914A1 (en) 2024-01-25
HK1245795A1 (zh) 2018-08-31
IL252849B (en) 2021-07-29
IL252849A0 (en) 2017-08-31
AU2020256336A1 (en) 2020-11-12
US20170355704A1 (en) 2017-12-14
JP2017538773A (ja) 2017-12-28
JP2021006564A (ja) 2021-01-21
RU2021100040A3 (enExample) 2021-04-26
US20210139490A1 (en) 2021-05-13
AU2015370588A1 (en) 2017-07-20
EP3237419A1 (en) 2017-11-01
MX2017008456A (es) 2018-03-01
KR20170117030A (ko) 2017-10-20
US10167294B2 (en) 2019-01-01
US20190211026A1 (en) 2019-07-11
RU2017126128A3 (enExample) 2019-06-13
BR112017013568A2 (pt) 2018-03-06
CA2971755A1 (en) 2016-06-30
JP7089566B2 (ja) 2022-06-22
MX369623B (es) 2019-11-14
US10793577B2 (en) 2020-10-06
AU2015370588B2 (en) 2020-07-16
RU2741387C2 (ru) 2021-01-25
CN107438612A (zh) 2017-12-05
US20250206753A1 (en) 2025-06-26
RU2021100040A (ru) 2021-02-02

Similar Documents

Publication Publication Date Title
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
JOP20200192A1 (ar) أجسام مضادة لـ tigit
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2017000806A1 (es) Compuestos anti-tnf
EA201691991A1 (ru) Мультиспецифические антитела
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
MX384024B (es) Peptidos macrociclicos utiles como inmunomoduladores.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201691582A1 (ru) Новые фармацевтические препараты
CR20160270A (es) ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
LT3210973T (lt) Heteroarilo junginiai, skirti akių ligų gydymui
MX382864B (es) Formulaciones de anticuerpos cristalinos.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2018014034A (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades.
DK3519050T3 (da) Sammensætninger til behandling af oftalmiske sygdomme